Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ionis Pharmaceuticals (NQ: IONS ) 50.74 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 50.74 Bid (Size) 47.48 (1) Ask (Size) 51.99 (1) Prev. Close 50.74 Today's Range 50.74 - 50.74 52wk Range 35.95 - 54.44 Shares Outstanding 141,797,854 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst July 22, 2024 Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... Via Benzinga Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong July 22, 2024 Biogen previously decided against opting into Ionis' Angelman program. Via Investor's Business Daily Performance YTD -4.03% -4.03% 1 Month +13.56% +13.56% 3 Month +19.53% +19.53% 6 Month +0.28% +0.28% 1 Year +27.33% +27.33% More News Read More The Latest Analyst Ratings For Ionis Pharmaceuticals July 16, 2024 Via Benzinga Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts June 27, 2024 Via Benzinga RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session June 24, 2024 Via Benzinga Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) June 03, 2024 Via Benzinga The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals May 08, 2024 Via Benzinga The Latest Analyst Ratings For Ionis Pharmaceuticals April 09, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals February 22, 2024 Via Benzinga Masters In Trading - Saturday, June 22 June 22, 2024 Via Talk Markets Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile May 31, 2024 Via Benzinga Exposures Product Safety Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder May 31, 2024 Via Benzinga Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another May 16, 2024 Via Benzinga Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis May 16, 2024 From Biogen Inc. Via GlobeNewswire Earnings Scheduled For February 21, 2024 February 21, 2024 Via Benzinga The 3 Most Undervalued Pharma Stocks to Buy in May 2024 May 09, 2024 Via InvestorPlace IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows March 13, 2024 Via Benzinga Are These 5 Undervalued Stocks Ready to Break Out? March 08, 2024 Via MarketBeat New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy March 06, 2024 From Biogen Inc. Via GlobeNewswire JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know February 01, 2024 Via Benzinga Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines January 31, 2024 Via Benzinga Exposures Product Safety Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study January 22, 2024 Via Benzinga Exposures Product Safety Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts January 18, 2024 Via Benzinga Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio January 08, 2024 From Praxis Precision Medicines, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
